The road to reimbursement for ‘Ilaris,’ a treatment used by around ten patients in Korea, continues to be bumpy ahead.

According to Dailypharm’s coverage, the government’s ‘reimbursement adequacy’ decision made for Novartis Korea’s Ilaris (canakinumab) has been put on hold after the company failed to meet the government's request for additional data. The drug, which is a treatment for hereditary recurrent fever syndrome, had previously received conditional approval from the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee.

Novartis has since requested the government to revisit the data submission requirements to the extent possible, and ha